Fosun Pharma: The holding subsidiary's drug LBP-ShC4 for treating male pattern baldness has been approved for clinical trials.

Fosun Pharma announced that its holding subsidiary, Shanghai Jiunji Health Technology Co., Ltd., has received approval from the National Medical Products Administration to conduct clinical trials for LBP-ShC4. LBP-ShC4 is a proprietary live biological therapeutic product developed by Fosun Pharma, intended for the treatment of male hormone-related hair loss. As of February 2026, the cumulative research and development investment for LBP-ShC4 is approximately 200 million yuan. As of the date of this announcement, there is currently no live biological therapeutic product approved for marketing globally to treat male hormone-related hair loss.